Sydney, Jan 13, 2026, 17:15 AEDT — After-hours
CSL Ltd shares dipped 1.0% to finish at A$173.32 on Tuesday, erasing a 0.46% gain from Monday and underperforming the broader Australian market. The stock fluctuated between A$173.32 and A$175.86 after kicking off at A$175.01, with roughly 683,000 shares traded.
The S&P/ASX 200 closed 0.56% higher, boosted by advances in gold, metals, mining, and materials shares, according to a market wrap from Investing.com.
The underperformance is pressing because investors are still grappling with last year’s reset: CSL cut its FY26 revenue and profit forecasts and postponed the spin-off of Seqirus, its flu vaccine division, after U.S. flu vaccination rates dropped more than anticipated. “We have seen a greater decline in influenza vaccination rates in the U.S. than we expected,” CEO Paul McKenzie told shareholders. Chairman Brian McNamee described the collapse as “remarkable.” Reuters
Tuesday brought no fresh updates to sway the discussion. CSL’s investor page lists its latest ASX filing as the Jan. 9 securities cessation notice.
There were signs of rotation in the market, with materials standing out as one of the stronger groups while some defensive sectors lagged, according to a live blog during the session.
Other major healthcare stocks fared better. Cochlear inched up 0.23%, while ResMed added roughly 0.54%, based on delayed quotes from Intelligent Investor.
CSL has been moving forward with a restructure after putting its demerger plans on hold. In August 2025, it announced plans to slash its workforce by up to 15% and to relaunch an on-market share buyback, aiming to repurchase A$750 million worth of shares in fiscal 2026.
The immediate challenge lies in execution. Any further slip in U.S. vaccination demand, delays in cost savings, or softer pricing for plasma-derived therapies could tighten margins and make investors wary.
With the market shut, all eyes shift to CSL’s upcoming event: the 2026 half-year results webcast set for 10 a.m. on Feb. 11 (AEDT). Traders will hunt for fresh details on guidance, updates on the Seqirus separation, and how quickly buybacks are progressing.
